Supply Chain Resilience Measures Included In Senate Coronavirus Bill
Executive Summary
Whether major drug shortages result from the COVID-19 pandemic or not, manufacturers would face greater reporting requirements, especially for APIs.
You may also be interested in...
COVID-19 Shows US FDA Why It Needs To Know Supply Chain’s Current And Surge Capacities
Agency begins gathering manufacturing plant data to prepare for disruptions that can drain inventories over a weekend.
COVID-19 Vaccines, Therapies Would Get Billion-Dollar Manufacturing Platform Under House Bill
House coronavirus legislation would boost domestic manufacturing capacity while further scrutinizing global supply chain.
Antibiotics May Finally Get Better Medicare Payments Under US Senate COVID-19 Aid Package
Provisions adapted from DISARM Act would carve out antimicrobials from hospital bundled payments and allow reimbursement equal to 100% of a drug’s average sales price.